Abstract Purpose Breast cancer-predisposing mutations PALB2 c.1027C[T (p.Gln343*) and PALB2 c.2167_2168delAT have each been observed multiple times in breast cancer families of Italian ancestry. More recently, the c2167_2168delAT mutation was identified in unrelated breast cancer cases of various ancestries. For each mutation, we investigated whether the origin was multiple mutational events (a ''hot-spot'') or a single event (a founder allele).
Methods We genotyped and reconstructed haplotypes for 36 participants of Italian, Italian-American, Hispanic, and Nigerian ancestries, using seven short tandem repeat (STR) markers that covered 3 Megabases within and flanking PALB2 on chromosome 16 . Results For PALB2 c.1027C[T, a shared haplotype with a minimum size of 150 kb was shared by all 19 carriers investigated, all of Italian ancestry. This result suggests that this allele arose as a single event in a shared ancestor. For PALB2 c.2167_2168delAT, all 12 carriers from American-Italian and Italian families shared a 1-Mb haplotype, the 3 Hispanic carriers shared a different haplotype of size 2 Mb, and the Nigerian carrier had different alleles at all 7 STR markers. These results suggest that PALB2 c.2167_2168delAT arose multiple times, but that within each population, PALB2 c.2167_2168delAT likely represents a single mutational event.
Conclusion We identified two PALB2 mutations that are founder alleles in Italian families, one of which is, Irene Catucci, Silvia Casadei and Yuan Chun Ding-Co-first authorship.
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Introduction
In 2006, PALB2 (partner and localizer of BRCA2), also known as FANCN, was identified as a key player in homologous recombination [1] . It was first described as a breast cancer-predisposing gene with identification of pathogenic mutations in familial cases [2] . Subsequent studies found carriers of truncating mutations in familial cases of almost all populations investigated with confirmation that pathogenic mutations were associated with breast cancer risk [3] . So far, more than 300 different mutations of PALB2 have been reported (http://databases. lovd.nl/shared/genes/PALB2), and it is included on clinical multigene breast cancer panels. We had previously identified a recurrent mutation-the c.1027C[T (p.Gln343*) in Northern Italy; it was detected in 6 of 113 familial cases and 2 of 477 controls, all from the Bergamo Province [4] . A second PALB2 mutation, c.2167_2168delAT (p.Met723Valfs*21), has been identified multiple times in individuals from geographically diverse areas by independent research groups. This mutation was found in an Italian and an Italian-American families, three Hispanic probands from Southern California, and a Nigerian proband ( [4] [5] [6] ; S. Neuhausen/J. Weitzel, personal communications; F. Olopade, personal communication). Because PALB2 c.1027C[T and c.2167_2168delAT mutations have been encountered in a number of breast cancer cases from either the same or from different ancestries, we investigated haplotypes to assess whether these recurrent mutations originated from independent or single mutational events.
Participants and methods

Subjects
Women with breast cancer and female controls were enrolled into research studies to identify breast cancer susceptibility genes. For the specific individuals in this study, they either carried or were a family member of a carrier with either a PALB2 c.1027C[T mutation (16 individuals from 4 independently ascertained families and 6 singleton carriers) or a PALB2 c.2167_2168delAT mutation (16 individuals from 2 independently ascertained families and 4 singleton probands). The 44 individuals were ascertained at the following centers: The Unit of (Table 1 ). All individuals participating in this study signed an informed consent to the use of their biological samples for research projects. The study was approved by the Ethics Committee of each participating center. PALB2 mutations were previously identified through Sanger sequencing or targeted next-generation sequencing ( [4, 7] ; Neuhausen personal communication). When available, relatives of PALB2 mutation carriers were genotyped for their family-specific mutations by Sanger sequencing using primers previously described [4, 8] .
Short tandem repeat (STR) marker genotyping
In total, 22 individuals were studied for haplotypes associated with PALB2 c.1027C[T mutation, and 20 individuals for the PALB2 c.2167_2168delAT mutation. Seven STR markers were selected, which span a region of approximately 3 Mb on chromosome 16p flanking and intersecting PALB2 (at chr16:23,614,483-23,652,678; hg19) ( Fig. 1 and Table S1 ). Four of the seven STR markers were custom developed for genotyping of PALB2 mutation carriers [8] , and three were STR markers previously deposited in the Marshfield comprehensive human genetic map [9, 10] . These markers were assayed by fluorescent PCR and capillary electrophoresis on an ABI PRISM 3130 or 3730xL Sequencer using standard methods. Primers and PCR conditions used to genotype the STR markers are reported in Supplementary 
Haplotype analysis
In families, haplotypes were reconstructed manually according to the known mutation status and the genotypes observed at each marker in the family members. In the families where it was not possible to reconstruct haplotypes with certainty, or in single individuals, haplotypes were 
Results
PALB2 c.1027C>T haplotype analysis
DNA samples extracted from the blood of 16 individuals from 4 families, and 6 single individuals, all of Italian/ Bergamo ancestry, were genotyped (Table 1 ; Fig. 2a ). Enlarged pedigrees with family cancer history were previously published for these individuals except for BG149 and BG363 [4] . Four haplotypes across the seven STR markers were reconstructed. A core haplotype is shared by all 19 mutation carriers ( Table 2 ; Fig. 2a ). This core haplotype, with a size of *0.15 Mb, is defined by recombination events 3 0 of PALB2 between markers D16S412 and 23622TCTA14 and 5 0 of PALB2 between markers D16S417 and D16S401 ( Fig. 1a ; Table 2 ). This shared haplotype indicates that the PALB2 c.1027C[T mutation occurred as a unique event in a single ancestor related to all 10 families in this study with this mutation.
PALB2 c.2167_2168delAT haplotype analysis
Germline DNA samples from 16 members of 2 families of Italian and American/Italian ancestry, 3 female breast cancer cases of Hispanic ancestry, and one female breast cancer case of Nigerian ancestry were genotyped (Table 1 ; Fig. 2b ). Haplotype construction suggests that there were three unique events ( Table 2 ). All 12 mutation carriers in the Italian and American/Italian families share a conserved haplotype, of approximate size of 1 Mb, defined by a recombination event 3
0 of PALB2 between markers D16S412 and 23622TCTA14 ( Fig. 1A ; Table 2 ). The three Hispanic individuals share a conserved haplotype of 2 Mb defined by a recombination event 5
0 of PALB2 between markers D16S417 and D16S401 ( Fig. 1A ; Table 2 ). The Nigerian breast cancer case carries alleles which are not a part of any of the previously described haplotypes. These unique events, at least in the Italian and Hispanic ancestry cases, resulted in independent founder mutations in these two populations.
Discussion
Overall, PALB2 loss-of-function mutations have been found in 0.6-3.9 % of high-risk breast cancer families, with an average cumulative risk of breast cancer of 35 % by the age of 70 years [5] . In this study, we describe the haplotype analysis of two recurrent PALB2 mutations. Five other truncating mutations have been identified to be recurrent in specific populations. The PALB2 c.509_510delGA (p.Arg170Ilefs*14) was found in Poland in 4/648 (0.6 %) familial breast cancer cases and in 1/1310 controls (0.08 %) [11] , with no evidence of shared alleles. This mutation was later detected in approximately 0.25 % of unselected breast cancer cases from Central and Eastern Europe [12] . With such a narrow distribution of the mutation, yet an apparent lack of a shared haplotype, it is not clear whether this is a single founder mutation or whether there were multiple mutation events at this site. breast cancer cases and in 0 of 6000 controls. Genotyping of four STR markers showed that mutation carriers shared common alleles, suggesting that the PALB2 c.2323C[T is a founder mutation [13] . In Finland, a recurrent founder mutation PALB2 c.1592delT (p.Leu531Cysfs*30) was identified [14] . They were able to estimate that this mutation was associated with a 40 % cumulative risk for developing breast cancer by the age of 70 years. In Australia, a founder PALB2 c.3113G[A (p.Trp1038* or complete or partial deletion of exon 10) was identified, and they estimated a 91 % cumulative risk of developing breast cancer by the age of 70 years [15] . Analyses of founder mutations allow for the determination of mutation-specific risks, which still vary by population and the extent of family history.
The common haplotype shared by all four Italian families and six Italian single individuals with the PALB2 c.1027C[T mutation suggests that this mutation occurred as a single event in an ancestor common to all the families and single individuals studied. This mutation, to our knowledge, has been found only in individuals from Bergamo and represents one of the few examples of populationspecific mutation in Italians. Its limited range to this specific area in Northern Italy may reflect limited migration of the local population, possibly due to territory geographical conformation characterized by several secluded valleys that may have caused genetic isolation [4] . Consistent with this hypothesis, the BRCA1 c.190T[C (p.Cys64Arg) founder mutation is only found in breast cancer families from Bergamo, and was estimated to be more than 3000 years old [16] . There are too few families and family members with the PALB2 c.1027C[T to estimate the age of the mutation. However, the shorter length of the PALB2 c.1027C[T haplotype with respect to the BRCA1 c.190C[T haplotype may indicate that the c.1027C[T is an older mutation.
PALB2 c.2167_2168delAT has been observed in individuals of African, Italian, and Hispanic ancestry. Based on haplotype and allele sharing, these mutations appear to represent different mutational events in each of the three populations. No haplotype sharing was observed among the Nigerian, Hispanic, and Italian carriers. However, a conserved haplotype was found between the ItalianAmerican family and the Italian family ascertained in Milan, representing evidence of a common ancestor. We investigated whether the Italian-American family (CF1908) and the Milan family (MI03) originated from the same geographic region in Italy. Surnames are often informative with respect to Italian region of origin [17] . The two ancestors in the Italian-American family, who migrated to America at the beginning of the 1900 century, were from Sasso Ferrato (AN) and Genga (AN), two small towns from the province of Ancona in the Italian Appennini Mountains, located at a distance of about 10 km from each other. In the Italian family from Milan, the paternal aunt of the proband was originally from Mondavio, a small town in the province of Pesaro-Urbino, 45 km from the above-mentioned locations (Fig. 3) . A genealogy search also found that, based on actual frequency and distribution, the family names originated from the region Marche in Central Italy, confirming the geographic origin of their families. The three Hispanic breast cancer cases share the same associated mutation alleles indicating a putative Amerindian mutational event (data not shown). This PALB2 mutation was identified in 3 of 188 unrelated Hispanic breast cancer cases (1.6 %), and we have since identified additional Hispanic breast cancer cases with this mutation (personal communication). Interestingly, the PALB2 c.2167_2168delAT appears to have arisen through multiple independent mutation events, and yet within populations, it appears likely to be a founder mutation.
In conclusion, we have identified two founder mutations of Italian ancestry, of which one is an independent founder in those of Amerindian ancestry.
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